UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel.
| Revenue (Most Recent Fiscal Year) | $90.40M |
| Net Income (Most Recent Fiscal Year) | $-126.87M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 9.22 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -160.04% |
| Net Margin (Trailing 12 Months) | -164.44% |
| Return on Equity (Trailing 12 Months) | -97487.15% |
| Return on Assets (Trailing 12 Months) | -59.38% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.14 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.99 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 1.37 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-0.21 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.05 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.96 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.32 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 46.26M |
| Free Float | 44.09M |
| Market Capitalization | $869.30M |
| Average Volume (Last 20 Days) | 1.08M |
| Beta (Past 60 Months) | 1.10 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.70% |
| Percentage Held By Institutions (Latest 13F Reports) | 91.29% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |